Previous 10 | Next 10 |
AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock PR Newswire REDWOOD CITY, Calif. , Jan. 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and...
Document Security Systems (DSS) -31% on stock offering.Gevo (GEVO) -25% on stock offering.BioLineRx (BLRX) -22% on equity offering.Bionano Genomics (BNGO) -19% on pricing of stock offering.Histogen (HSTO) -12% on FDA clinical hold of planned study for HST-003.AcelRx P...
Gainers: [[PCTI]] +20.5%. [[GRTS]] +19.1%. [[NFLX]] +11.9%. [[CLFD]] +11.8%. [[BRMK]] +7.5%.Losers: [[ACRX]] -12.8%. [[PERI]] -8.3%. [[LAC]] -8.3%. [[DSS]] -8.2%. [[SYRS]] -7.7%. For further details see: PCTI, NFLX, ACRX and DSS among after-hours movers
AcelRx Pharmaceuticals (ACRX) has announced an underwritten public offering of its common stock.Where all shares to be sold in the offering will be sold by AcelRx.Underwriters granted 30-day option to purchase up to an additional 15% of the number of shares offered. Net proceeds will be ...
AcelRx Announces Underwritten Public Offering of Common Stock PR Newswire REDWOOD CITY, Calif. , Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commerciali...
AcelRx Pharma shares jump ([[ACRX]] +25.7%) after it announces investigator-initiated study with University Hospitals ((UH)) Cleveland Medical Center to evaluate the postoperative use of its opioid drug Dsuvia in a prospective cohort of patients undergoing cardiac sur...
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen PR Newswire REDWOOD CITY, Calif. , Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical c...
Are You Following Analysts On These Penny Stocks? This year has gotten off to a strong start already. That goes for penny stocks & blue-chips alike. Many stocks are reaching new 52-week and all-time highs. Meanwhile, the broader markets have weathered the economic storm well. Bu...
AcelRx Pharmaceuticals ([[ACRX]] -4.0%) achieved 348 formulary approvals through the close of 2020, marking it a significant achievement with COVID-related restrictions and delays.Preliminary FY20 revenues are estimated at $5.4M.Cash and equivalents along-with short-term investments...
AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements PR Newswire REDWOOD CITY, Calif. , Jan. 14, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commerciali...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...